Drug Search Results
More Filters [+]

AUTO-9

Alternative Names: AUTO-9, AUTO9
Latest Update: 2024-05-17
Latest Update Note: Clinical Trial Update

Product Description

Autolus is developing a T-cell therapy targeting CD33, CD123, and CLL1 for the treatment of Acute Myeloid Leukemia. (Sourced from: https://www.autolus.com/media/e4al2yhk/q2-2023-ppt-final-3-8-23.pdf)

Mechanisms of Action: CAR-T,CD33,CD123,CLL1

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Autolus Limited
Company Location: LONDON X0 W12 7RZ
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AUTO-9

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title